Merck Foundation Launches $20 Million Initiative to Advance Equity in U.S. Cancer Care

National effort builds on Foundation's longstanding commitment to helping patients in underserved communities receive high-quality, equitable care

The Merck Foundation (the Foundation) announced today the launch of the Alliance for Equity in Cancer Care (the Alliance), a $20 million, five-year initiative, designed to make cancer care more equitable in the United States by helping patients living in underserved communities receive timely access to high-quality, culturally responsive care.

"The severity of the need to take action on advancing equity in cancer care cannot be overstated and will not be overlooked," said Carmen Villar, CEO of the Merck Foundation. "We must move with urgency and work together to provide all people living with cancer access to high-quality care and treatment. The creation of the Alliance is an important step toward ensuring social determinants of health no longer factor into an individual's ability to receive vital health care."

As part of the initiative, the Foundation is providing grants to select non-profit health care organizations to help develop and implement evidence-informed, innovative programs that advance equity in cancer care. Grantees will work collectively to improve the coordination of patient care from diagnosis through survivorship; strengthen patient engagement in treatment decisions and overall patient-provider communication; build community partnerships that address barriers to care related to social determinants of health; and provide essential psychosocial support services.

Alliance program grantees include:

Nearly 40% of Americans will be diagnosed with cancer in their lifetime. Members of racial and ethnic minority groups, those living in rural areas, low-income individuals and the uninsured are disproportionately affected by cancer, yet often have limited access to cancer screenings, care and treatment. As a result, they may experience later stage diagnoses, delays in treatment and decreased adherence to cancer therapies – with serious negative consequences to their health.

The Foundation is also supporting a National Program Office at Virginia Commonwealth University (VCU) Massey Cancer Center , in partnership with the VCU Center on Health Disparities , which will assist Alliance program grantees in building partnerships with community-based organizations and provide technical assistance to support their programs. Additionally, the National Program Office will evaluate the effectiveness of Alliance programs and identify and promote best practices to enhance the delivery of cancer care in the United States.

"There is no one-size-fits-all approach to making sure that cancer care is equitable," says Robert Winn, M.D., director of VCU Massey Cancer Center and director of the Alliance National Program Office. "We are supporting diverse approaches – driven by local community needs – to reduce the unacceptable disparities in cancer care. We hope to improve the lives of people living with cancer and help transform how health systems deliver care so that it meets the medical and social needs of patients."

The Alliance builds on the Foundation's legacy of investing in community-focused programs that advance health equity as it follows other national, multi-year program investments to reduce health disparities and improve access to high-quality care, such as the Alliance to Advance Patient-Centered Cancer Care , Bridging the Gap in Diabetes Care and HIV Care Connect .

About the Merck Foundation

The Merck Foundation is a U.S.-based, private charitable foundation. Established in 1957 by Merck, a leading global biopharmaceutical company, the Foundation is funded entirely by the company and is Merck's chief source of funding support to qualified non-profit charitable organizations. Since its inception, the Foundation has contributed nearly $1 billion to support important initiatives that address critical global health and societal needs that are consistent with Merck's purpose: to save and improve lives around the world. For more information, visit www.merck.com/company-overview/esg/philanthropy/

Media Contacts:

Patrick Ryan
(973) 275-7075

Leland Laury
(610) 659-8856

News Provided by Business Wire via QuoteMedia

MRK
The Conversation (0)
Merck Announces First-Quarter 2023 Financial Results

Merck Announces First-Quarter 2023 Financial Results

First Quarter 2023 Reflected Continued Strong Underlying Performance Across Key Growth Drivers, Particularly in Oncology and Vaccines Total Worldwide Sales Were $14.5 Billion, a Decrease of 9% From First Quarter 2022; Excluding LAGEVRIO, Growth Was 11%; Excluding LAGEVRIO and the Impact of... Keep Reading...
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Spectrum Pharmaceuticals, Inc. , BELLUS Health Inc , Prometheus Biosciences, Inc. , Univar Solutions Inc.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Spectrum Pharmaceuticals, Inc. , BELLUS Health Inc , Prometheus Biosciences, Inc. , Univar Solutions Inc.

Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847. There is no cost or financial obligation to you.... Keep Reading...
OTC:BCTXF

BriaCell Announces Grant to Investigator Dr. Saveri Bhattacharya at Sidney Kimmel Cancer Center – Jefferson Health

Highlights: Grant awarded to Dr. Saveri Bhattacharya, Principal Investigator of the Phase I/IIa combination study of Bria-IMT™ with KEYTRUDA® (by Merck) in advanced breast cancer at Thomas Jefferson University. Merck to provide KEYTRUDA® for use in the combination study. The Investigator Grant... Keep Reading...

Merck Announces Q4 and Full-Year 2019 Financial Results

Merck (NYSE:MRK) reported quarterly worldwide sales at US$11.9 billion in Q4 in its financial results for the fourth quarter of 2019 and its full fiscal 2019 year. As quoted in the press release: As evidenced by our results and our 2020 guidance, Merck had an extraordinary year and is in a... Keep Reading...
OTC:BCTXF

BriaCell’s Clinical Data Accepted to be Presented at the Annual Symposium of Society of Surgical Oncology 2020 in Boston

Safety and early efficacy data to be presented from clinical trial of Bria-IMT™ in combination with immune checkpoint inhibitors in advanced breast cancer: Bria-IMT™ in combination with pembrolizumab (KEYTRUDA®; by Merck & Co., Inc.); Bria-IMT™ in combination with INCMGA00012 (by Incyte... Keep Reading...
Medicine capsule showing active ingredients.

5 Biggest Pharma Stocks in 2025

The pharmaceutical industry is a major player in the overall life science sector, responsible for developing and manufacturing the majority of prescription drugs. Companies in this space are constantly researching and creating innovative treatments for various medical conditions. In recent... Keep Reading...
Seegnal Inc. (TSXV:SEGN)

Seegnal Inc. Announces Extension of Maccabi Health Services Contract

Seegnal Inc. (TSXV: SEGN) ("Seegnal" or the "Corporation"), a global leader in SaaS clinical division support solutions, is pleased to announce that effective September 8, 2025, it has amended its contract with Maccabi Health Services ("Maccabi") for an additional six years and has also expanded... Keep Reading...
Numinus Wellness Inc. Announces Third Quarter Fiscal 2025 Results

Numinus Wellness Inc. Announces Third Quarter Fiscal 2025 Results

All financial results are reported in Canadian dollars unless otherwise stated. Numinus Wellness Inc. (TSX: NUMI) (OTCQB: NUMIF) (FSE: LR23) ("Numinus" or the "Company") a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based... Keep Reading...
Invion Executive Chair and CEO Thian Chew.

Invion CEO Maps Path to Peer-level Valuation as Momentum for Cancer Treatment Trials Builds

Invion (ASX:IVX) Executive Chair and CEO Thian Chew says the company sees a path to a rerate toward clinical-stage oncology peers — typically valued from AU$30 million to AU$40 million up to several hundred million — if it executes on a trio of near-term priorities: simplifying licencing,... Keep Reading...
Numinus Wellness Inc. Announces Second Quarter Fiscal 2025 Results

Numinus Wellness Inc. Announces Second Quarter Fiscal 2025 Results

All financial results are reported in Canadian dollars unless otherwise stated. Numinus Wellness Inc. (TSX: NUMI) (OTCQB: NUMIF) (FSE: LR23) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based... Keep Reading...

Latest Press Releases

Related News